Literature DB >> 1573422

Efficacy of intranasal administration of neostigmine in myasthenic patients.

A Sghirlanzoni1, D Pareyson, C Benvenuti, G Cei, V Cosi, M Lombardi, M Nicora, R Ricciardi, F Cornelio.   

Abstract

The efficacy of intranasally administered neostigmine was tested in 22 patients with generalized myasthenia gravis (MG). Topical therapy to the highly vascularized oropharynx proved to be quickly effective in 5-15 min both clinically and electrophysiologically. Twenty-eight MG patients were then recruited from different centres and their morning doses of oral pyridostigmine were substituted with intranasal neostigmine over a period of 2 or 3 weeks. Intranasal neostigmine proved to be equally efficacious in this regimen. No side-effect was noted even in 4 patients treated in this way for 1 year. Intranasal administration of anti-acetylcholinesterase may be very beneficial: (1) for patients with irregular absorption of oral doses; (2) early in the morning and every time a fast and temporary effect is needed; (3) in bulbar impairment and emergencies, in which a handy atomizer may be life-saving.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1573422     DOI: 10.1007/bf00833919

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  6 in total

1.  Intranasal drug delivery by spray and drops.

Authors:  J G Hardy; S W Lee; C G Wilson
Journal:  J Pharm Pharmacol       Date:  1985-05       Impact factor: 3.765

2.  Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis.

Authors:  R Mantegazza; C Antozzi; D Peluchetti; A Sghirlanzoni; F Cornelio
Journal:  J Neurol       Date:  1988-11       Impact factor: 4.849

3.  Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis.

Authors:  S M Aquilonius; S A Eckernäs; P Hartvig; B Lindström; P O Osterman; E Stålberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-10       Impact factor: 10.154

4.  Myasthenia gravis: prolonged treatment with steroids.

Authors:  A Sghirlanzoni; D Peluchetti; R Mantegazza; F Fiacchino; F Cornelio
Journal:  Neurology       Date:  1984-02       Impact factor: 9.910

5.  New antigen for antibody detection in myasthenia gravis.

Authors:  C Gotti; R Mantegazza; F Clementi
Journal:  Neurology       Date:  1984-03       Impact factor: 9.910

6.  Topical therapy for oropharyngeal symptoms of myasthenia gravis.

Authors:  J M Dooley; K J Goulden; J G Gatien; E J Gibson; B S Brown
Journal:  Ann Neurol       Date:  1986-02       Impact factor: 10.422

  6 in total
  3 in total

1.  Intramuscular neostigmine and glycopyrrolate safely accelerated bowel evacuation in patients with spinal cord injury and defecatory disorders.

Authors:  Alan S Rosman; Geeta Chaparala; Amit Monga; Ann M Spungen; William A Bauman; Mark A Korsten
Journal:  Dig Dis Sci       Date:  2008-03-13       Impact factor: 3.199

2.  Early Treatment with Intranasal Neostigmine Reduces Mortality in a Mouse Model of Naja naja (Indian Cobra) Envenomation.

Authors:  Matthew R Lewin; Stephen P Samuel; David S Wexler; Philip Bickler; Sakthivel Vaiyapuri; Brett D Mensh
Journal:  J Trop Med       Date:  2014-05-14

3.  Reversal of experimental paralysis in a human by intranasal neostigmine aerosol suggests a novel approach to the early treatment of neurotoxic envenomation.

Authors:  Matthew R Lewin; Philip Bickler; Tom Heier; John Feiner; Lance Montauk; Brett Mensh
Journal:  Clin Case Rep       Date:  2013-07-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.